Hypertensive Crisis

Hypertensive Crisis

Hypertensive crisis is a spectrum of severe blood pressure elevation associated with actual or potential acute target-organ damage. It is broadly classified into:

Hypertensive Emergency
Hypertensive Urgency (The 2024 AHA Scientific Statement and 2025 AHA/ACC Hypertension Guideline recommend abandoning the term “hypertensive urgency.” Instead, patients are classified as:severe asymptomatic hypertension)

Table of Contents

Hypertensive Emergency

Severe elevation of BP associated with acute target-organ injury(patient already diagnosed with CKD present with High B.P is not hypertensive emergency it is urgency)
Typically:SBP ≥180 mmHg and/or DBP ≥120 mmHg OR MAP of at least >135 mm (this value is not universal as it depends on baseline B.P)
therefore:
Absolute BP number is less important than relative change in blood pressure from baseline
Emergencies can occur at lower BP, especially in:
- Pregnancy
- Acute glomerulonephritis
- Pheochromocytoma
- Children

Clinical Features

Symptoms depend on organ involved.

Organ	Manifestation
Brain	Hypertensive encephalopathy, stroke,PRES
Heart	ACS, LV failure, pulmonary edema
Aorta	Aortic dissection
Kidney	AKI
Retina	Papilledema, retinal hemorrhage
Pregnancy	Eclampsia

Hypertensive Urgency

Severe BP elevation WITHOUT acute target-organ damage.
Usually:SBP ≥180 mmHg or DBP ≥120 mmHg
Patients may have:Headache/Anxiety/Mild dyspnea/Epistaxis

Epidemiology

~1–2% of hypertensive patients develop hypertensive crisis.
Hypertensive emergencies account for:~25% of hypertensive crises
Most common in:
- Chronic uncontrolled hypertension
- Nonadherence to medications
- CKD
- Elderly
- Substance abuse (cocaine, amphetamines)

Causes

Cause / Category	Examples / Notes
Chronic hypertension	Most common overall cause
Medication noncompliance	Poor adherence; sudden withdrawal of clonidine or β-blockers,Alcohol or benzodiazepine
Reversible causes	Volume overload.Hypercapnia, or nonadherence with CPAP or BiPAP therapy for sleep disordered.,Pain,Anxiety, agitation. Urinary obstruction.
Renal disease	CKD, glomerulonephritis (GN), renal artery stenosis (RAS),Scleroderma renal crisis.
Endocrine disorders	Pheochromocytoma, hyperaldosteronism, Cushing syndrome, thyrotoxicosis
Drugs / Substances	Cocaine, amphetamines, MAO inhibitors, NSAIDs, erythropoietin, calcineurin inhibitors,Steroids
Pregnancy	Severe preeclampsia, eclampsia
Neurologic disorders	Stroke, head injury,Autonomic dysreflexia following spinal cord injury

Diagnostic Evaluation

History

Duration of hypertension/Medication adherence
Drug use/Pregnancy
Baseline B.P
Neurologic symptoms/Chest pain/Dyspnea/visual disturbance, headache

Physical Examination

BP—Both arms—Repeated measurements
Neurologic exam
Fundoscopy
Cardiovascular exam
Volume status

Investigations

Test	Purpose
CBC	Hemolysis, anemia
RFT	AKI
Electrolytes	End-organ dysfunction
Urinalysis	Proteinuria, hematuria
ECG	Ischemia/LVH
Troponin	ACS
Chest X-ray	Pulmonary edema

Condition	Imaging
Stroke	CT/MRI brain
Aortic dissection	CT angiography
Pulmonary edema	Echo
PRES	MRI brain

Management

First treat the reversible causes because if you give antihypertensive first and later reversible cause resolves it will cause overshoot hypotension
Not every hypertensive emergency requires an arterial line.
Most ICU patients receiving continuous IV antihypertensive infusions benefit from one.
Essential in aortic dissection and strongly recommended in patients needing precise, beat-to-beat BP control (e.g., ICH, severe hypertensive encephalopathy, rapidly titrated vasodilator therapy).
If the patient is stable and BP can be safely managed with intermittent non-invasive measurements, an arterial line is not routinely mandatory.

Lower BP in a controlled manner.Excessively rapid lowering can cause:

Stroke
Myocardial ischemia
Renal ischemia

because chronic hypertensive patients have shifted autoregulation curves.

BP Reduction Targets

Most Hypertensive Emergencies

Goal:Reduce MAP by 20–25% within first hour(AHA-2025)
Then:BP to ~160/100–110 mmHg over next 6 hours
Then gradual normalization over 24–48 hours.

Exceptions

Condition	BP Goal
Aortic dissection	SBP <120 within 20 min
Eclampsia	SBP <160, DBP <105
Ischemic stroke thrombolysis candidate	<185/110
ICH	SBP ~140
PRES	Controlled rapid reduction
Pheochromocytoma CRISIS	SBP <140 within first hour

Preferred Drugs According to Clinical Scenario

Clinical Scenario	Preferred Drugs
Aortic dissection	Esmolol + Nicardipine/Nitroprusside
Acute pulmonary edema	Nitroglycerin, Clevidipine, Nicardipine
Hypertensive encephalopathy	Nicardipine, Labetalol
Intracerebral hemorrhage	Nicardipine, Clevidipine
Ischemic stroke	Nicardipine, Labetalol
Preeclampsia/eclampsia	Labetalol, Hydralazine, Nicardipine + Magnesium sulfate
Cocaine/amphetamine crisis	Benzodiazepines + Phentolamine/Nicardipine
Acute coronary syndrome	Nitroglycerin + Beta blocker
Acute renal failure	Fenoldopam, Nicardipine

IV Drugs Used in Hypertensive Emergency

Drug	Dose	Contraindications / Major Avoidance Situations
Nicardipine-(DHP-CCB)(2nd-Best infusion agent)	IV infusion: Start 5 mg/h, increase by 2.5 mg/h every 5–15 min until target BP achieved. Maximum: 15 mg/h.When Bp reaches target, reduce the infusion to 3-5 mg/hr to prevent accumulation.	C.I-Cirrhosis,Strong CYP 3A4 inhibitors,Acute coronary ischemia (may cause reflex tachycardia). S.E-Reflex tachycardia. Peripheral edema due to vasodilation. Headache. Nausea/vomiting.
Clevidipine-(DHP-CCB)(Best infusion agent)	IV infusion: Start 1–2 mg/h; double dose every 90 sec initially, then titrate every 5–10 min. Typical: 4–6 mg/h. Max ~21–32 mg/h depending on protocol.	C.I- hypertriglyceridemia and pancreatitis.Allergy to soybeans or eggs. S.E-Reflex tachycardia. Peripheral edema due to vasodilation. Headache. Nausea/vomiting.
Labetalol	Bolus: 20 mg IV over 2 min → then 40-60–80 mg-80-80 every 10 min as needed (max cumulative ~300 mg).If a total dose of 300mg doesn’t work, switch to another agent. Infusion: 0.5–2 mg/min.(infusion dose accumulates so try to avoid)	Asthma, COPD with bronchospasm, bradycardia, second/third-degree AV block, cardiogenic shock, acute decompensated heart failure, severe peripheral vascular disease, cocaine intoxication with unopposed α activity concern (relative).
Esmolol	Loading: 500 mcg/kg over 1 min → infusion 50 mcg/kg/min; titrate up to 300 mcg/kg/min.	Asthma, COPD with bronchospasm, bradycardia, second/third-degree AV block, cardiogenic shock, acute decompensated heart failure,
Metoprolol	IV: 2.5–5 mg every 5 min up to 15 mg total(equivalent to ~37.5 mg PO metoprolol tartrate). 1:2.5 conversion from IV to PO.example Response to 10 mg IV –> Start metoprolol tartrate 25 mg PO q6hr.The first oral dose can be started 20 minutes after the initial IV dose Note-metoprolol tartrate (immediate release formulation),metoprolol succinate (XR formulation given daily)
Nitroglycerin	IV infusion: Start 5 mcg/min; increase by 5 mcg/min every 3–5 min. Higher doses (100–200 mcg/min or more) may be needed in pulmonary edema. tachyphylaxis often develops within 24-48 hours. For SCAPE- Loading 400-800 mcg/min for 2.5 minutes.	S.E—Hypotension,Reflex tachycardia,Headache (most patients),Methemoglobinemia (rare; may relate to G6PD deficiency or dose). C.I—right ventricular infarction, severe aortic stenosis, hypertrophic obstructive cardiomyopathy, recent PDE-5 inhibitor use (sildenafil within 24 h; tadalafil within 48 h), raised ICP .
Nitroprusside	IV infusion: 0.3–0.5 mcg/kg/min initially; titrate to max 10 mcg/kg/min (avoid prolonged >>48 hours high-dose use).Due to potency, intra-arterial BP monitoring is recommended to prevent “overshoot.	C.I—Renal failure (risk of thiocyanate toxicity), hepatic failure (cyanide toxicity), pregnancy, raised intracranial pressure, vitamin B12 deficiency, optic atrophy, Leber hereditary optic neuropathy, Recent use of phosphodiesterase inhibitors (e.g., sildenafil) tachyphylaxis often develops within 24-48 hours.
Hydralazine(Arteriolar vasodilator)	IV/IM: 5–20 mg every 4–6 h as needed.maximum cumulative IV dose 40 mg.1:2-1:4 IV to PO conversion	Coronary artery disease due to reflex tachycardia , aortic dissection, tachyarrhythmias, hypertrophic cardiomyopathy, lupus (long-term use concern), severe tachycardia.
Fenoldopam	IV infusion: Start 0.1 mcg/kg/min; titrate every 15 min. Typical 0.1–1.6 mcg/kg/min.	Glaucoma, increased intraocular pressure, sulfite allergy, tachycardia.
Phentolamine	IV bolus: 5–15 mg slow IV; repeat as required.	Coronary artery disease, peptic ulcer disease, recent MI (relative).
Enalaprilat	IV: 0.625–1.25 mg every 6 h; may increase to 5 mg every 6 h.only IV form of an ACEi/ARB.	Pregnancy, bilateral renal artery stenosis, hyperkalemia, acute kidney injury, angioedema history with ACE inhibitors.
Urapidil (not universally available)	IV bolus: 10–50 mg slowly, then infusion 5–40 mg/h.	Aortic isthmus stenosis, AV shunts, severe bradycardia, cardiogenic shock.
Propranolol	IV: 1 mg over 1 min; repeat every 2 min up to 5 mg.??	Other uses Arrhythmias, especially ventricular arrhythmias (e.g., VT storm)-Propranolol 40 mg PO q6h Paroxysmal sympathetic hyperactivity(40 mg PO q6hr) Anxiolysis-Propranolol 40 mg PO q6h Essential tremor. Migraine prophylaxis.

When to Transition to Oral Medication?

Patient should meet ALL of the following

Criteria	Requirement
Target BP achieved	Desired BP reached for that specific emergency (not necessarily normal BP)
IV infusion stable	Minimal or no dose adjustments for 6–24 hours (depends on condition)
Target-organ injury stabilized	No ongoing neurological deterioration, myocardial ischemia, pulmonary edema, etc.
Hemodynamically stable	No hypotension or major BP fluctuations
Able to take oral medications	Awake, swallowing safely, functioning GI tract (or enteral tube available)
No immediate need for rapidly titratable therapy	BP no longer requires minute-to-minute adjustment

How to Transition

Step 1 – Identify the Cause

Choose medications based on the underlying disease, not just the BP.

Condition	Preferred Oral Drugs
General hypertension	ACEI/ARB + CCB ± thiazide
CAD/Post-MI	β-blocker + ACEI/ARB
Heart failure	ACEI/ARB/ARNI + β-blocker + MRA
CKD with albuminuria	ACEI/ARB
Aortic dissection	β-blocker first, then ACEI/ARB or CCB if needed
Pregnancy	Labetalol, nifedipine ER

Step 2 – Start Oral Medication Before Stopping the IV Infusion

Do not stop the infusion first.
Give the first oral dose while the IV infusion is still running to allow time for the oral medication to take effect.
Amlodipine very late onset of action – little role for acute BP management.
Metoprolol drops the heart rate, but is relatively ineffective for controlling blood pressure.

Step 3 – Gradually Wean the IV Infusion

Avoid abrupt discontinuation.

Example:

Reduce infusion by 25–50%
Observe BP for 30–60 minutes
If BP remains stable, reduce further
Stop infusion once oral therapy is effective

Hypertensive Urgency Management

NO Need Of aggressive rapid B.P lowering therefore Urgency is misnomer.BP reduction Gradual over days to weeks
There is NO need for referral to the emergency department.(AHA-2017)
There is NO need for hospital admission.(AHA-2017)

Management:

Identify reversible causes(Pain, anxiety, urinary retention, hypoxia, hypercapnia, alcohol withdrawal, medication noncompliance, sympathomimetics, NSAIDs, steroids, excess IV fluids, etc. Treat these first.)
Routine extensive work-up is not required solely because BP is elevated.
Reinstitute missed medications
Intensify Oral antihypertensives
Observe briefly if needed to ensure stability, not necessarily until BP normalizes.
Follow-up within days
Long-term outpatient target—Usually <130/80 mmHg for most adults, individualized based on age, frailty, CKD, diabetes, ASCVD risk, etc.

Drugs to Avoid for “Hypertensive Urgency” (Asymptomatic Markedly Elevated BP)

Drug	Reason
Sublingual or immediate-release nifedipine	Can cause abrupt hypotension, myocardial ischemia, stroke
Routine IV labetalol, nicardipine, clevidipine, nitroprusside	Reserved for hypertensive emergency with acute target-organ damage
Routine use of oral clonidine or hydralazine solely to normalize BP before discharge	May produce unpredictable BP reduction without improving outcomes; focus should be on optimizing chronic therapy and arranging follow-up rather than rapid normalization.

Oral Drugs in Hypertensive Urgency

Drug (Class)	Dose	Side Effects / Contraindications (CI)
Amlodipine (DHP-CCB)	5 mg OD (2.5 mg in elderly/frail) → Increase by 2.5–5 mg every 1–2 weeks → 10 mg/day	SE: Pedal edema, flushing, headache, dizziness, palpitations, gingival hyperplasia.Safe in CKD and diabetes.
Nifedipine ER (DHP-CCB)	30 mg OD → Increase every 1–2 weeks → 90–120 mg/day(formulation dependent)	SE: Edema, headache, flushing, reflex tachycardia. CI: Avoid immediate-release/sublingual nifedipine (can cause stroke/MI from abrupt hypotension).
Lisinopril (ACEI)	10 mg OD (5 mg if on diuretic/CKD) → Double every 2–4 weeks → 40 mg/day	SE: Dry cough, hyperkalemia, AKI, angioedema. CI: Pregnancy, bilateral renal artery stenosis, previous ACEI angioedema, K⁺ >5.5 mmol/L,AKI.
Enalapril	5 mg OD/BD → Increase every 1–2 weeks → 40 mg/day	Same as ACE inhibitors.
Ramipril	2.5 mg OD → Increase every 2 weeks → 20 mg/day	Same ACEI adverse effects.
Losartan (ARB)	50 mg OD (25 mg if elderly/volume depleted) → Increase after 2–4 weeks → 100 mg/day	SE: Hyperkalemia, AKI, dizziness. CI: Pregnancy, bilateral renal artery stenosis. Lower risk of cough/angioedema than ACEIs.
Valsartan	80 mg OD → Increase every 2 weeks → 320 mg/day	Same as ARBs.
Telmisartan	40 mg OD → Increase after 2–4 weeks → 80 mg/day	Same as ARBs.
Olmesartan	20 mg OD → Increase after 2 weeks → 40 mg/day	SE: Hyperkalemia, rare sprue-like enteropathy. CI: Pregnancy.
Hydrochlorothiazide (Thiazide)	12.5–25 mg OD → Increase after 2–4 weeks → 50 mg/day(little benefit >25 mg)	SE: Hypokalemia, hyponatremia, hyperuricemia, hyperglycemia, photosensitivity. CI: Anuria, caution in gout.
Chlorthalidone (Preferred Thiazide-like)	12.5 mg OD → Increase after 2–4 weeks → 25 mg/day(occasionally 50 mg)	SE: More hypokalemia than HCTZ, hyponatremia, hyperuricemia. CI: Anuria. Better outcome data than HCTZ.
Metoprolol Succinate (β1-selective)	25–50 mg OD → Double every 1–2 weeks → 200 mg/day	SE: Bradycardia, fatigue, depression, sexual dysfunction. CI:Severe bradycardia, AV block, cardiogenic shock. Use mainly if CAD, HF, AF.
Bisoprolol	2.5–5 mg OD → Increase every 2 weeks → 20 mg/day	Same β-blocker adverse effects.
Atenolol	25–50 mg OD → Increase every 2 weeks → 100 mg/day	Same β-blocker adverse effects. Requires renal dose adjustment.
Carvedilol (α+β blocker)	6.25 mg BD → Double every 1–2 weeks → 25 mg BD (50 mg/day)	SE: Orthostatic hypotension, bradycardia. CI: Severe asthma, AV block, cardiogenic shock. Preferred in HFrEF.
labetalol	200 mg B.D,maximal dose is 2400 mg/day	in pregnancy, high doses may pose a risk of fetal bradycardia.
Prazosin	1-2 mg HS → Increase gradually To B.D/T.D.S →Max dose 20 mg/day(10 mg B.D)	Same as α-blockers; marked first-dose hypotension.Orthostatic hypotension and falls.Drowsiness.Headache, vertigo, nausea. Not a first-line chronic agent but can be used for resistant hypertension.
Clonidine (Central α2-agonist)	0.1 mg BD → Increase every few days → 0.6–0.8 mg/day	SE: Sedation, dry mouth, constipation, rebound hypertension if stopped abruptly. CI: Avoid routine use for asymptomatic markedly elevated BP; avoid abrupt withdrawal.
Methyldopa	250 mg BD/TDS → Increase every 2 days → 3 g/day	SE: Sedation, hepatitis, Coombs-positive hemolytic anemia. CI:Active liver disease. Preferred in pregnancy.
Hydralazine (Oral)	Arteriolar vasodilator decreases systemic vascular resistance and generally increases cardiac output. 10–25 mg TDS–QID → Increase every 2–5 days → 300 mg/day(100mg TDS)—Dose adjustment needed in renal failure	SE: Headache, reflex tachycardia, edema, drug-induced lupus. CI: CAD, tachyarrhythmias,Aortic dissection,High-output heart failure,connective tissue diseases (hydralazine may cause medication-induced lupus). Not a first-line chronic agent.
Spironolactone (MRA)	25 mg OD → Increase after 4 weeks → 100 mg/day	SE: Hyperkalemia, gynecomastia, menstrual irregularities. CI:K⁺ >5 mmol/L, eGFR <30 mL/min/1.73 m², Addison disease. Preferred add-on for resistant hypertension.
Eplerenone (MRA)	25 mg OD → Increase after 4 weeks → 50 mg BD (100 mg/day)	SE: Hyperkalemia; less endocrine effects than spironolactone. CI: Hyperkalemia, severe CKD.

Renal Dose Adjustment Required

Lisinopril, Enalapril.Ramipril, Perindopril
Olmesartan (severe CKD)
Bisoprolol
Atenolol,Nebivolol, Methyldopa
⚠️ Clonidine
⚠️ Hydralazine (severe CKD)

Avoid or Use with Extreme Caution

❌ Spironolactone (eGFR <30 or hyperkalemia)
❌ Eplerenone (significant CKD)
⚠️ Hydrochlorothiazide (ineffective when eGFR <30)
⚠️ Indapamide (avoid in severe renal failure)

Remember the pattern:

ACE inhibitors → Dose adjustment required.
Most ARBs → No routine dose adjustment, but monitor renal function and potassium.

Stepwise Approach to Oral Antihypertensive Therapy

According to the 2025 ACC/AHA Hypertension Guideline, 2024 AHA Scientific Statement, and standard hypertension management principles, the approach depends on how far the BP is above goal, current medications, and patient characteristics—not simply on the absolute BP at presentation.

Clinical Situation	Recommended Approach	Reason
Not taking any antihypertensive (new diagnosis or stopped medication)	Start 1 or 2 first-line drugsdepending on BP level	Initiate long-term therapy rather than trying to normalize BP immediately
Missed medications/non-adherence	Restart previous regimen (if appropriate)	Most patients improve without changing drugs
On one drug at low/moderate dose	Increase toward target dose oradd another class	Depends on BP elevation and drug tolerance
On one drug at maximum tolerated dose	Add a second first-line drug	Better BP reduction than further dose escalation if already near max
On two drugs at reasonable doses	Add third first-line drug	Standard triple therapy
On ACEI/ARB + CCB + thiazide but uncontrolled	Add spironolactone	Preferred fourth-line agent (PATHWAY-2)

Why Add Another Drug Instead of Doubling Dose?

Approximate BP reduction:

Intervention	SBP Reduction
Double dose of same drug	↓ 2–5 mmHg
Add second first-line drug	↓ 8–15 mmHg

General Titration Timeline

Stage	Time
Start medication	Day 0
Reassess BP	2–4 weeks
If not at goal	Increase dose or add another first-line drug
Reassess	Every 2–4 weeks until goal reached
Stable	Follow-up every 3–6 months

Malignant Hypertension

Malignant hypertension is a medical emergency characterized by:

Severely elevated blood pressure (usually SBP ≥180 mmHg and/or DBP ≥120 mmHg, although there is no absolute BP threshold)
Grade IV hypertensive retinopathy, specifically:
- Papilledema (hallmark)
- Often accompanied by retinal hemorrhages and/or cotton-wool spots

Acute target-organ damage, making it a subtype of hypertensive emergency.

Key point: Modern guidelines emphasize acute target-organ damage rather than a specific BP value. Malignant hypertension is not diagnosed by BP alone.

Historical vs Modern Terminology

Older Term	Modern Interpretation
Accelerated hypertension	Severe hypertension with retinal hemorrhages/exudates (Grade III retinopathy) but no papilledema
Malignant hypertension	Severe hypertension with papilledema (Grade IV retinopathy) ± other organ damage
Hypertensive emergency	Umbrella term for severe hypertension with acute target-organ injury; malignant hypertension is one subtype

Many contemporary guidelines use “hypertensive emergency” preferentially, but malignant hypertension remains a recognized clinical diagnosis when papilledema is present.

Pathophysiology

Severe BP elevation

↓

Failure of autoregulation

↓

Endothelial injury

↓

Fibrinoid necrosis of arterioles

↓

Platelet activation + thrombosis

↓

Microvascular ischemia

↓

Brain • Retina • Kidney • Heart injury

References

Indian Society of Critical Care Medicine (ISCCM). ISCCM Protocol Book. 3r ed. New Delhi: Jaypee Brothers Medical Publishers; 2025.
Cline DM, Ma OJ, Cydulka RK, Meckler GD, Thomas SH, Handel DA, et al. The Washington Manual of Emergency Medicine. 4th ed. Philadelphia: Wolters Kluwer; 2023.
Writing Committee Members, Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension.2025;82(10):e212-e316. doi:10.1161/HYP.0000000000000249.